Понравилась презентация – покажи это...
3 Stocks That Soared Stupendously This Week
Health-care was hot this week. Lots of stocks jumped saw solid double-digit gains. Few performed as nicely as these three big winners, though. 1 2 3
Shares of the maker of small-molecule drugs jumped nearly 33% higher for the week. PTC Therapeutics (Nasdaq:PTCT) Source: Yahoo! Finance
Europe’s Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for PTC’s translarna Translarna targets treatment of rare disease nonsense mutation Duchenne muscular dystrophy, or nmDMD PTC still must await a final decision by the European Medicines Agency, which is expected in a few months Why PTC shot up PDQ
Shares of the biotech skyrocketed 38% this week. Prosensa Holding N.V. (Nasdaq:RNA) Source: Yahoo! Finance
In a somewhat strange twist, Prosensa’s stock actually rose more than PTC Therapeutics’ shares on PTC’s good news in Europe Prosensa is also hoping to win European approval for its Duchenne Muscular Dystrophy (DMD) drug, drisapersen The other big player in the DMD arena, Sarepta Therapeutics (Nasdaq:SRPT), also received a nice 8% bump for the week Sarepta’s shares, however, have already surged a lot since mid-April and didn’t get quite the jolt felt by Prosensa and PTC Why Prosensa shares popped
Shares of the biotech specializing in drugs that treat eye disease vaulted 22% higher this week. Ophthotech Corp (Nasdaq:OPHT) Source: Yahoo! Finance
Ophthotech landed a licensing deal with Novartis (NYSE:NVS) for Fovista Fovista targets treatment of patients newly diagnosed with wet AMD, a chronic eye disease Novartis gains marketing rights for Fovista outside of the U.S. with Ophthotech keeping U.S. rights The deal could be worth $1 billion to Ophotech over time Why Ophthotech shares took off
Really, all of this week’s big winners could keep the momentum going PTC Therapeutics looks to have a great shot at obtaining European approval for translarna Prosensa also seems to have a good chance at getting a positive decision across the Atlantic for drisapersen Novartis’ endorsement of Fovista – accompanied by a nice $200 million upfront payment – bodes well for Ophotech While any of these stocks could experience a pullback after this week’s big gains, all could be winners over the long run Best pick to keep soaring? ?
Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!